Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13887515 | 0.86 | GRIN2D (0.43) | MIFGRIN2BALDH1A1SMN1; SMN2 | |
| SCHEMBL14270116 | 0.79 | IDO1 (0.37) | IDO1 | |
| SCHEMBL13855831 | 0.78 | HTR3E (0.52) | TAAR1IDO1AGXTGRIN2B | |
| SCHEMBL14648573 | 0.77 | TAAR1 (0.46) | TAAR1IDO1P2RX7 | |
| SCHEMBL14872978 | 0.77 | PDE2A (0.39) | IDO1GRIN2BALDH1A1SMN1; SMN2 | |
| SCHEMBL16401935 | 0.77 | ENPP2 (0.48) | MIFTAAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18795026 | 0.77 | CYP1A2 (0.53) | IDO1GRIN2BSMN1; SMN2 | |
| SCHEMBL16097145 | 0.77 | TAAR1 (0.46) | TAAR1IDO1AGXTSMN1; SMN2 | |
| SCHEMBL13921682 | 0.77 | MAOB (0.47) | GRIN2BALDH1A1 | |
| SCHEMBL16363565 | 0.77 | MIF (0.57) | MIFTAAR1IDO1GRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994141-A | Phenylthiazole derivative with anti-liver cancer and anti-inflammatory activities and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118994140-A | Triazole derivative with antidepressant effect, and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | claimed |
| CN-115636817-A | Isatin derivative containing triazole ring and preparation method and application thereof | 山东大学 | 2023-01-24 | — | — | CN | claimed |
| CN-109705095-B | Fused ring p-benzoquinone CDC25 protein phosphatase inhibitor containing triazole ring, and preparation method and application thereof | 山东大学 | 2021-06-08 | — | — | CN | claimed |
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-18 | — | — | US | disclosed |
| WO-2025104092-A1 | MODULATORS OF SEPTIN 6 FOR USE IN THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025104081-A1 | TRIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-05-22 | — | — | WO | disclosed |
| CN-118994140-A | Triazole derivative with antidepressant effect, and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994141-A | Phenylthiazole derivative with anti-liver cancer and anti-inflammatory activities and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-115636817-B | Isatin derivative containing triazole ring, and preparation method and application thereof | 山东大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-115232126-B | Beta-carbolin-1, 2, 3-triazole compound, preparation method thereof and application of compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-04-25 | — | — | CN | disclosed |
| CN-115636817-A | Isatin derivative containing triazole ring and preparation method and application thereof | 山东大学 | 2023-01-24 | — | — | CN | disclosed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | disclosed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009060053-A1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | CBX2, CBX3, CBX6 | MIF 4076/4885TAAR1 2357/4885IDO1 892/4885 |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FASN | MIF 3551/4885TAAR1 4356/4885IDO1 1095/4885 |
| US-20130281499-A1 | COMPOUNDS | CYP11B2, SCD, CYP11B1 | MIF 1278/4885TAAR1 4555/4885IDO1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.